Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Aims: To determine the baseline characteristics and glucose‐lowering therapies associated with weight change among patients with type 2 diabetes. Methods: Eleven thousand one hundred and forty participants in the ADVANCE trial were randomly assigned to an intensive [aiming for a haemoglobin A1c (HbA1c) ≤6.5%] or a standard blood glucose‐control strategy. Weight was measured at baseline and every 6 months over a median follow‐up of 5 years. Multivariable linear regression and linear‐mixed effect models were used to examine predictors of weight change. Results: The mean difference in weight between the intensive and standard glucose‐control arm during follow‐up was 0.75 kg (95% CI: 0.56–0.94), p‐value <0.001. The mean weight decreased by 0.70 kg (95% CI: 0.53–0.87), p < 0.001 by the end of follow‐up in the standard arm but remained stable in the intensive arm, with a non‐significant gain of 0.16 kg (95% CI: −0.02 to 0.34), p = 0.075. Baseline factors associated with weight gain were younger age, higher HbA1c, Caucasian ethnicity and number of glucose‐lowering medications. Treatment combinations including insulin [3.22 kg (95% CI: 2.92–3.52)] and thiazolidinediones [3.06 kg (95% CI: 2.69–3.43)] were associated with the greatest weight gain while treatment combinations including sulphonylureas were associated with less weight gain [0.71 kg (95%CI: 0.39–1.03)]. Conclusions: Intensive glucose‐control regimens are not necessarily associated with substantial weight gain. Patient characteristic associated with weight change were age, ethnicity, smoking and HbA1c. The main treatment strategies predicting weight gain were the use of insulin and thiazolidinediones.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Phung, O. J. (2010) · JAMA · doi:10.1001/jama.2010.405 · Cited by 520
Cited by
Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship
Mesinovic, J., Zengin, A., De Courten, B., Ebeling, P. R., & Scott, D. (2019) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s186600 · Cited by 553
Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
Van Gaal, L., & Scheen, A. (2015) · Diabetes Care · doi:10.2337/dc14-1630 · Cited by 221
Personalized type 2 diabetes management: an update on recent advances and recommendations
Williams, D. M., Jones, H., & Stephens, J. W. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s331654 · Cited by 121
Bowering, K., Case, C., Harvey, J., Reeves, M., Sampson, M., Strzinek, R., Bretler, D.-M., Bang, R. B., & Bode, B. W. (2017) · Diabetes Care · doi:10.2337/dc16-1770 · Cited by 119
“7 kg over 26 weeks for both treatment groups, which is typical of the weight gain associated with intensive insulin regimens (28).”
BackgroundFactors associated with weight gain in people with type 2 diabetes starting on insulin
Balkau, B., Home, P. D., Vincent, M., Marre, M., & Freemantle, N. (2014) · Diabetes Care · doi:10.2337/dc13-3010 · Cited by 77
“In the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation) trial, 19% of the type 2 diabetic patients were newly treated with insulin during the 5-year trial (19).”
Background
Metadata
- Authors
- van Dieren, S., Czernichow, S., Chalmers, J., Kengne, A. P., de Galan, B. E., Poulter, N., Woodward, M., Beulens, J. W. J., Grobbee, D. E., van der Schouw, Y. T., & Zoungas, S.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2012-02-08
- Volume
- 14
- Issue
- 5
- Pages
- 464-469
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2083260646
- Cited by
- 50
- References
- 4
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial. https://app.cochat.ai/papers/10.1111/j.1463-1326.2012.01556.x
- The paper
- van Dieren, S., Czernichow, S., Chalmers, J., Kengne, A. P., de Galan, B. E., Poulter, N., Woodward, M., Beulens, J. W. J., Grobbee, D. E., van der Schouw, Y. T., & Zoungas, S. (2012). Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2012.01556.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.